Asia-Pacific Cancer Biomarker Market Trends 2019 | Segmentation, Outlook, Industry Report to 2025

Asia-Pacific cancer biomarkers market is growing at a CAGR of around 11.9% during the forecast period. APAC is both a strong and promising market for biomarkers. This is particularly due to the strong population base, high prevalence of cancer in Asian countries such as China, Japan. Half of the global incidence of cancer is projected to occur in Asia with 22% in China and 7% in India alone. Biomarker development and adoption in these Asian countries will reduce the economic burden of cancer on the respective governments by timely and efficient diagnosis of diseases.

To Request a Sample of our Report on Asia-Pacific Cancer Biomarker Market: https://www.omrglobal.com/request-sample/asia-pacific-cancer-biomarker-market

Changing lifestyles, increasing urbanization, changes in reproductive patterns and diet, obesity, tobacco use, alcohol drinking, chronic infection and increasing lifespans contribute to an ever-increasing cancer burden and changing cancer pattern in Asian countries. The projected increase will be largest in low-resource and medium-resource countries in Asia. The cancer biomarker market has huge opportunities in APAC due to increase in cancer cases, increase in R&D and growing medical tourism. China is the second largest economy after the US and China has the world's largest population (1.4 billion), followed by India (1.3 billion). Both China and India hold 40% of total world population share. As population of India and China grows, its expanding share of older adults is particularly notable.

The United Nations Population Division projects that in India's population with age 50 years and older will reach 34% by 2050. Between 2010 and 2050, the share of 65 and older is expected to increase from 5% to 14%, while the share in the oldest age group (80 and older) will triple from 1% to 3%. Furthermore, Chinese authorities are projecting the country's aged population (above 60 years old) will reach 255 million by 2020. The country's ageing population will grow at an average rate of 6.4 million a year. By 2020, there will be 255 million elders, representing at least 17.8% of the entire Chinese population. With the age dynamics, cancer cases in Asia Pacific are expected to grow.

(Get 15% Discount on Buying this Report)

A full Report of Asia-Pacific Cancer Biomarker Market is Available @ https://www.omrglobal.com/industry-reports/asia-pacific-cancer-biomarker-market

Asia-Pacific Cancer Biomarker Market Segmentation

By Biomarker Type

· Genetic Biomarker

· Protein Biomarker

By Cancer Type

· Lung Cancer

· Prostate Cancer

· Breast Cancer

· Colorectal Cancer

· Cervical Cancer

· Other

By Applications

· Drug Discovery and Development

· Diagnosis

· Risk Assessment

· Prognostics

By Profiling Technology

· Omics Technology

· Immunoassays

· Cytogenetics

· Bioinformatics

Regional Analysis

· China

· India

· Japan

Rest of Asia-Pacific

Company Profiles

· Abbott laboratories Inc.

· Astellas Pharma Inc.

· Becton, Dickson and Co.

· Bio-Rad Laboratories, Inc.

· Danaher Corp.

· F. Hoffmann-La Roche Ltd.

· Merck and Co., Inc.

· Novartis AG

· Pfizer Inc.

· QIAGEN GmbH

· Thermo Fisher Scientific Inc.

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.